Appointment of NED

RNS Number : 6428B

Creo Medical Group PLC

03 February 2020

 

Creo Medical Group plc

("Creo" the "Company" or the "Group")

Appointment of NED

Creo Medical Group plc (AIM: CREO), a medical device company focused on the emerging field of surgical endoscopy, announces the appointment of Ivonne Cantu as an independent Non-Executive Director to the Company with effect from 1 February 2020.

Ivonne has extensive experience in corporate finance acting as corporate finance adviser to UK and international companies for more than 20 years at Cenkos Securities plc and previously at Merrill Lynch. Ivonne is currently Director of Investor Relations and Corporate Development at Benchmark Holdings plc, the AIM listed aquaculture technology company.  Ivonne holds a BSc in Engineering from Universidad Panamericana and an MBA from the Wharton School of Business.

On appointment, Ivonne will become Chair of the Company's Remuneration Committee.

Charles Spicer, Non- Executive Chairman of Creo, said: "We are pleased to welcome Ivonne to the Board. She has known Creo since we were a private company and brings a wealth of experience from her career in the City, which we are confident will make a major contribution to the success of Creo."

Ivonne Maria Gloria Cantu (aged 51), holds or has held the following directorships in the past five years:

Current Directorships	Directorships held within the last five years
La Vida -  Vital Investment for Development Aid in Latin America (trustee)	Cenkos Securities (Trustees) Limited

Ivonne Cantu does not hold any ordinary shares in the Company. There are no further details to be disclosed pursuant to Schedule Two Paragraph (g) of the AIM Rules for Companies.

Enquiries:

Creo Medical Group plc	investors.creomedical.com
Richard Rees (CFO)	[phone]
Cenkos Securities	[phone]
Stephen Keys / Cameron MacRitchie (NOMAD)
Michael Johnson / Russell Kerr (Sales)
Walbrook PR Ltd	Tel: [phone] or [e-mail]
Paul McManus / Lianne Cawthorne	Mob: [phone]

About Creo Medical

Creo Medical, founded in 2003, is a medical device company focused on the development and commercialisation of minimally invasive surgical devices, by bringing advanced energy to endoscopy.  The Company's mission is to improve patient outcomes by applying microwave and RF energy to surgical endoscopy.  Creo has developed CROMA, an electrosurgical Advanced Energy Platform that combines bipolar radiofrequency for precise localised cutting and microwave for controlled coagulation.  This technology provides clinicians with flexible, accurate and controlled surgical solutions.

The Company's strategy is to bring its CROMA Advanced Energy Platform powered by unique full spectrum adaptive technology to market enabling a suite of medical devices which the Company has designed, initially for the emerging field of GI therapeutic endoscopy, an area with high unmet needs.  The CROMA Advanced Energy platform will be developed further for bronchoscopy and laparoscopy procedures.  The Company believes its technology can impact the landscape of surgery and endoscopy by providing a safer, less-invasive and more cost-efficient option of treatment.

For more information about Creo Medical please see our website, investors.creomedical.com

 

END

 

 

BOAKZGFMVMFGGZM